Recruiting
Phase 2

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Sponsor:

Edgewise Therapeutics, Inc.

Code:

NCT05291091

Conditions

Becker Muscular Dystrophy

Eligibility Criteria

Sex: Male

Age: 12 - 50

Healthy Volunteers: Not accepted

Interventions

Sevasemten 10 mg

Sevasemten 5 mg

Sevasemten 12.5 mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information